Reliant Technologies, Inc. Receives FDA Clearance for Fraxel Re:Pair™ Laser System

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Reliant Technologies, Inc., the pioneer of fractional resurfacing and market leader of aesthetic laser skin treatments, today announced its Fraxel re:pair laser system has received FDA clearance for ablation, coagulation and skin resurfacing, based on ongoing results from two rounds of clinical trials. The Fraxel re:pair system provides the industry’s first and only Fractional Deep Dermal Ablation (FDDATM) treatment, which leads to tissue contraction, tightening and collagen remodeling. The Fraxel re:pair laser removes and eliminates aged and damaged skin without the prolonged downtime and adverse reactions associated with conventional ablative resurfacing lasers (also known as CO2 or erbium YAG lasers) and surgical procedures.

Back to news